Charles Marcus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Charles Marcus has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Rathan M. Subramaniam
Dean's Office, Otago Medical School, University of Otago, Dunedin, New Zealand
4 shared publicationsAditya Bagrodia
Department of Urology, UT Southwestern Medical Center, Dallas, TX
1 shared publicationGreg Avey
Department of Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Ave #3284, Madison, WI 53792, USA
1 shared publicationPeter Butler
Department of Radiology, UT Southwestern Medical Center, Dallas, TX
1 shared publicationSara Sheikhbahaei
Department of Radiology, Johns Hopkins Medical Institutions, 601 N. Caroline Street, JHOC 3235, Baltimore, MD 21287, USA
1 shared publicationSuzanne Cole
Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX
1 shared publication
Latest Publications
- 4 March 2022
- Published by Elsevier in PET Clinics
- Vol. 17 (2) , 223-234
PET Imaging of Oral Cavity and Oropharyngeal Cancers
- 4 March 2022
- Published by Elsevier in PET Clinics
- Vol. 17 (2) , 223-234
PET Imaging of Oral Cavity and Oropharyngeal Cancers
- 1 September 2021
- Published by Elsevier in Radiologic Clinics of North America
- Vol. 59 (5) , 773-788
PET Imaging for Head and Neck Cancers
- 1 September 2021
- Published by Elsevier in Radiologic Clinics of North America
- Vol. 59 (5) , 773-788
PET Imaging for Head and Neck Cancers
- 1 January 2021
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 51 (1) , 68-78
Role of Non-FDG-PET/CT in Head and Neck Cancer
- 1 January 2021
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 51 (1) , 68-78
Role of Non-FDG-PET/CT in Head and Neck Cancer
- 1 August 2020
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 215 (2) , 267-276
Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management
OBJECTIVE. The purpose of this article is to review the utility of F-18-fluciclovine PET/CT in the evaluation of recurrent prostate cancer. CONCLUSION. Fluorine-18-labeled fluciclovine PET/CT has shown promise in the evaluation of recurrent prostate cancer. Its performance has been superior to that of other imaging modalities. It has had good diagnostic accuracy, especially in the detection of extraprostatic disease recurrence, and the findings have an impact on treatment planning Gallium-68-labeled prostate-specific membrane antigen PET/CT has also had excellent performance in the detection of biochemically recurrent prostate cancer with detection rates superior to those of fluciclovine PET/CT.
- 1 August 2020
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 215 (2) , 267-276
Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management
OBJECTIVE. The purpose of this article is to review the utility of F-18-fluciclovine PET/CT in the evaluation of recurrent prostate cancer. CONCLUSION. Fluorine-18-labeled fluciclovine PET/CT has shown promise in the evaluation of recurrent prostate cancer. Its performance has been superior to that of other imaging modalities. It has had good diagnostic accuracy, especially in the detection of extraprostatic disease recurrence, and the findings have an impact on treatment planning Gallium-68-labeled prostate-specific membrane antigen PET/CT has also had excellent performance in the detection of biochemically recurrent prostate cancer with detection rates superior to those of fluciclovine PET/CT.